We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.90 surpassed the Zacks Consensus Estimate by 4.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 4.1%, on average.
Let’s check out the factors that have shaped BDX’s performance prior to this announcement.
Factors to Note Before BDX Reports
BD Medical Essentials
BD Medical Essentials’ performance in the third quarter of fiscal 2026 is expected to have remained steady, supported by trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment delivered growth driven by continued market share expansion in the United States across its Medical Delivery Solutions (MDS) and Specimen Management businesses. MDS benefited from sustained momentum in U.S. Vascular Access Management, while Specimen Management was supported by continued strength in the BD Vacutainer portfolio. However, these gains were partially offset by continued volume-based procurement headwinds in China, which weighed on overall segment growth. Management also indicated that China remained one of the focused areas of pressure across the portfolio, suggesting these market dynamics are likely to have persisted in the to-be-reported quarter.
During the quarter, BDX continued to expand its Medical Essentials portfolio with the commercial launch of the BD CentroVena One Insertion System and the earlier introduction of the BD Vacutainer Urine Complete Cup Kit, which are expected to have witnessed robust product adoption.
The Zacks Consensus Estimate for third-quarter fiscal 2026 BD Medical Essentials revenues is currently pegged at $1.66 billion.
BD Interventional
BD Interventional’s performance in the third quarter of fiscal 2026 is expected to have remained strong, reflecting trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment delivered solid growth across its businesses. The Urology and Critical Care business continued to benefit from strength in the PureWick portfolio. Surgery’s performance was driven by strength in Infection Prevention and Advanced Tissue Regeneration, while Peripheral Intervention benefited from robust growth in Peripheral Vascular Disease and Oncology. However, continued market dynamics in China partially offset growth within the Peripheral Intervention business. These factors are likely to have persisted in the to-be-reported quarter, supporting overall segmental revenues while continuing to weigh on performance in China.
During the quarter, BDX continued to strengthen its Interventional portfolio through multiple product introductions. The company launched the Elyra Thulium Fiber Laser System in the United States to expand its kidney stone care portfolio, received FDA clearance for the Surgiphor 1000mL antimicrobial irrigation system and introduced the Revello Vascular Covered Stent across CE-mark-accepting European countries following CE Mark approval. These products are expected to have witnessed robust adoption, thereby driving the segmental revenues in the to-be-reported quarter.
The Zacks Consensus Estimate for third-quarter fiscal 2026 BD Interventional revenues is currently pegged at $1.39 billion, suggesting an uptick of 4.9% from the year-ago quarter’s reported figure.
Other Factors Likely to Affect BDX
BD Connected Care’s performance in the third quarter of fiscal 2026 is expected to have remained resilient, reflecting trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment delivered growth led by Advanced Patient Monitoring, driven by continued strength in U.S. consumables demand. Medication Management Solutions recorded modest growth, as a difficult prior-year comparison in Alaris capital was offset by strong infusion sets performance, supported by increased utilization following the prior-year fluid supply disruption and pull-through from Alaris market share gains. These trends are likely to have continued in the to-be-reported quarter, supporting segmental revenues.
BD BioPharma Systems’ performance in the third quarter of fiscal 2026 is expected to have remained under pressure, reflecting trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment declined as lower demand for vaccine products more than offset continued strength in the Biologics business, driven by GLP-1 programs. Management continued to identify vaccines as a focused area of pressure across the portfolio, suggesting these headwinds are likely to have persisted in the to-be-reported quarter and continued to weigh on segmental revenues.
BD’s Estimate Picture
For third-quarter fiscal 2026, the Zacks Consensus Estimate for revenues is pegged at $4.89 billion, implying a decline of 11.2% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $3.14, indicating a decrease of 14.7% from the prior-year period’s reported number.
What Our Model Suggests About BDX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: BD has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Over the past three months, BD’s shares have gained 17.3%, outperforming the Medical - Dental Supplies’ 14% rise. BDX’s shares also outperformed the Zacks Medical sector’s increase of 7.2% and the S&P 500’s growth of 4.2%.
Three Months Price Comparison
Image Source: Zacks Investment Research
BD’s peer, Cardinal Health, Inc. (CAH - Free Report) , has outperformed the company, while its other peers like West Pharmaceutical Services, Inc. (WST - Free Report) and Align Technology, Inc. (ALGN - Free Report) have underperformed it. CAH, WST and ALGN’s shares are up 21.9%, 11.6% and down 0.4%, respectively, in the same time frame.
View the Zacks #1 Rank List
Image: Bigstock
Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?
Key Takeaways
Becton Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to report third-quarter fiscal 2026 results on Aug. 6, before market open.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.90 surpassed the Zacks Consensus Estimate by 4.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 4.1%, on average.
Let’s check out the factors that have shaped BDX’s performance prior to this announcement.
Factors to Note Before BDX Reports
BD Medical Essentials
BD Medical Essentials’ performance in the third quarter of fiscal 2026 is expected to have remained steady, supported by trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment delivered growth driven by continued market share expansion in the United States across its Medical Delivery Solutions (MDS) and Specimen Management businesses. MDS benefited from sustained momentum in U.S. Vascular Access Management, while Specimen Management was supported by continued strength in the BD Vacutainer portfolio. However, these gains were partially offset by continued volume-based procurement headwinds in China, which weighed on overall segment growth. Management also indicated that China remained one of the focused areas of pressure across the portfolio, suggesting these market dynamics are likely to have persisted in the to-be-reported quarter.
During the quarter, BDX continued to expand its Medical Essentials portfolio with the commercial launch of the BD CentroVena One Insertion System and the earlier introduction of the BD Vacutainer Urine Complete Cup Kit, which are expected to have witnessed robust product adoption.
The Zacks Consensus Estimate for third-quarter fiscal 2026 BD Medical Essentials revenues is currently pegged at $1.66 billion.
BD Interventional
BD Interventional’s performance in the third quarter of fiscal 2026 is expected to have remained strong, reflecting trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment delivered solid growth across its businesses. The Urology and Critical Care business continued to benefit from strength in the PureWick portfolio. Surgery’s performance was driven by strength in Infection Prevention and Advanced Tissue Regeneration, while Peripheral Intervention benefited from robust growth in Peripheral Vascular Disease and Oncology. However, continued market dynamics in China partially offset growth within the Peripheral Intervention business. These factors are likely to have persisted in the to-be-reported quarter, supporting overall segmental revenues while continuing to weigh on performance in China.
During the quarter, BDX continued to strengthen its Interventional portfolio through multiple product introductions. The company launched the Elyra Thulium Fiber Laser System in the United States to expand its kidney stone care portfolio, received FDA clearance for the Surgiphor 1000mL antimicrobial irrigation system and introduced the Revello Vascular Covered Stent across CE-mark-accepting European countries following CE Mark approval. These products are expected to have witnessed robust adoption, thereby driving the segmental revenues in the to-be-reported quarter.
The Zacks Consensus Estimate for third-quarter fiscal 2026 BD Interventional revenues is currently pegged at $1.39 billion, suggesting an uptick of 4.9% from the year-ago quarter’s reported figure.
Other Factors Likely to Affect BDX
BD Connected Care’s performance in the third quarter of fiscal 2026 is expected to have remained resilient, reflecting trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment delivered growth led by Advanced Patient Monitoring, driven by continued strength in U.S. consumables demand. Medication Management Solutions recorded modest growth, as a difficult prior-year comparison in Alaris capital was offset by strong infusion sets performance, supported by increased utilization following the prior-year fluid supply disruption and pull-through from Alaris market share gains. These trends are likely to have continued in the to-be-reported quarter, supporting segmental revenues.
BD BioPharma Systems’ performance in the third quarter of fiscal 2026 is expected to have remained under pressure, reflecting trends observed in the fiscal second quarter. In second-quarter fiscal 2026, the segment declined as lower demand for vaccine products more than offset continued strength in the Biologics business, driven by GLP-1 programs. Management continued to identify vaccines as a focused area of pressure across the portfolio, suggesting these headwinds are likely to have persisted in the to-be-reported quarter and continued to weigh on segmental revenues.
BD’s Estimate Picture
For third-quarter fiscal 2026, the Zacks Consensus Estimate for revenues is pegged at $4.89 billion, implying a decline of 11.2% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $3.14, indicating a decrease of 14.7% from the prior-year period’s reported number.
What Our Model Suggests About BDX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: BD has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company price-eps-surprise | Becton, Dickinson and Company Quote
BD’s Share Price Performance
Over the past three months, BD’s shares have gained 17.3%, outperforming the Medical - Dental Supplies’ 14% rise. BDX’s shares also outperformed the Zacks Medical sector’s increase of 7.2% and the S&P 500’s growth of 4.2%.
Three Months Price Comparison
Image Source: Zacks Investment Research
BD’s peer, Cardinal Health, Inc. (CAH - Free Report) , has outperformed the company, while its other peers like West Pharmaceutical Services, Inc. (WST - Free Report) and Align Technology, Inc. (ALGN - Free Report) have underperformed it. CAH, WST and ALGN’s shares are up 21.9%, 11.6% and down 0.4%, respectively, in the same time frame.